You are here

  • Home
  • Archive
  • Volume 66, Issue 8
  • A comparison between interferon gamma release assays and the tuberculin skin test in the contact tracing of patients with chronic kidney disease

Article Text

Article menu
Download PDFPDF
PostScript
Letter to the Editor
A comparison between interferon gamma release assays and the tuberculin skin test in the contact tracing of patients with chronic kidney disease
  1. D W Connell1,
  2. A Singanayagam1,
  3. R Charif2,
  4. P M George1,
  5. P L Molyneaux1,
  6. C McCrudden1,
  7. M Magtoto1,
  8. E Harden3,
  9. S L Seneviratne3,
  10. N D Duncan2,
  11. O M Kon1
  1. 1TB Service, Imperial College Healthcare NHS Trust, London, UK
  2. 2West London Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK
  3. 3Department of Immunology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK
  1. Correspondence to Dr David W Connell, Department of Chest and Allergy, St. Mary's Hospital, Imperial College Healthcare NHS Trust, Praed Street, London, W2 1NY, UK; d.connell{at}imperial.ac.uk

https://doi.org/10.1136/thx.2010.149088

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We welcome the recent guidelines from the British Thoracic Society on the management of Mycobacterium tuberculosis infection and disease in patients with chronic kidney disease (CKD).1 We note the paucity of evidence (particularly from the UK) in this population regarding the use of interferon gamma release assays (IGRA) in screening patients for latent tuberculosis infection (LTBI).

    We present data to show the first UK-based cohort comparing the tuberculin skin test (TST) and the two commercially available IGRA—T-SPOT.TB (Oxford Immunotec, Abingdon, UK) and Quantiferon-Gold-in-Tube (Cellestis, Carnegie, Australia)—in a population of inpatients with CKD. It involves the follow-up of 61 patients from a renal inpatient ward who were screened …

    View Full Text

    Footnotes

    • Linked articles 150102.

    • Competing interests None.

    • Provenance and peer review Not commissioned; not externally peer reviewed.

    Linked Articles

    • PostScript
      Authors' response
      Heather Milburn Neil Ashman Peter Davies
      Thorax 2010; 66 730-730 Published Online First: 14 Oct 2010. doi: 10.1136/thx.2010.150102